

DAFTAR PUSTAKA

- Aisyah, D. N., Mayadewi, C. A., Diva, H., Kozlakidis, Z., Siswanto, & Adisasmito, W. (2020). A spatial-temporal description of the SARS-CoV-2 infections in Indonesia during the first six months of outbreak. *PloS One*, 15(12), e0243703. <https://doi.org/10.1371/journal.pone.0243703>
- Amraotkar, A. R., Bushau-Sprinkle, A. M., Keith, R. J., Hamorsky, K. T., Palmer, K. E., Gao, H., Rai, S. N., & Bhatnagar, A. (2022). Pre-Existing Comorbidities Diminish the Likelihood of Seropositivity after SARS-CoV-2 Vaccination. *Vaccines*, 10(8). <https://doi.org/10.3390/vaccines10081363>
- Barrière, J., Chamoirey, E., Adjoutah, Z., Castelnau, O., Mahamat, A., Marco, S., Petit, E., Leysalle, A., Raimondi, V., & Carles, M. (2021). Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors. *Annals of Oncology*, 32(8), 1053–1055. <https://doi.org/10.1016/j.annonc.2021.04.019>
- Boroumand, A. B., Forouhi, M., Karimi, F., Moghadam, A. S., Naeini, L. G., Kokabian, P., & Naderi, D. (2022). Immunogenicity of COVID-19 vaccines in patients with diabetes mellitus: A systematic review. *Frontiers in Immunology*, 13, 940357. <https://doi.org/10.3389/fimmu.2022.940357>
- Buntinx, E., Brochado, L., Borja-Tabora, C., Yu, C. Y., Alberto, E. R., Montellano, M. E. B., Carlos, J. C., Toloza, L. B., Hites, M., Siber, G., Clemens, R., Ambrosino, D., Qin, H., L., Han, H. H., Hu, B., Li, P., Baccarini, C., & Smolenov, I. (2023). Immunogenicity of an adjuvanted SARS-CoV-2 trimeric S-protein subunit vaccine (S-2P) in SARS-CoV-2-naïve and exposed individuals in a phase 2/3, double-blind,



randomized study. *Vaccine*, 41(11), 1875–1884.
<https://doi.org/10.1016/j.vaccine.2023.02.017>

Collier, D. A., Ferreira, I. A. T. M., Kotagiri, P., Datir, R. P., Lim, E. Y., Touizer, E., Meng, B., Abdullahi, A., Collaboration, T. C.-N. B. C.-19, Elmer, A., Kingston, N., Graves, B., Gresley, E. L., Caputo, D., Bergamaschi, L., Smith, K. G. C., Bradley, J. R., Ceron-Gutierrez, L., Cortes-Acevedo, P., ... Gupta, R. K. (2021). Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. *Nature*, 596(7872), 417.
<https://doi.org/10.1038/s41586-021-03739-1>

Dietz, L. L., Juhl, A. K., Søgaaard, O. S., Reekie, J., Nielsen, H., Johansen, I. S., Benfield, T., Wiese, L., Stærke, N. B., Jensen, T. Ø., Jakobsen, S. F., Olesen, R., Iversen, K., Fogh, K., Bodilsen, J., Petersen, K. T., Larsen, L., Madsen, L. W., Lindvig, S. O., ... Tolstrup, M. (2023). Impact of age and comorbidities on SARS-CoV-2 vaccine-induced T cell immunity. *Communications Medicine*, 3(1), 58. <https://doi.org/10.1038/s43856-023-00277-x>

Ellulu, M. S., Patimah, I., Khaza'ai, H., Rahmat, A., & Abed, Y. (2016). Obesity and inflammation: The linking mechanism and the complications. *Archives of Medical Science : AMS*, 13(4), 851. <https://doi.org/10.5114/aoms.2016.58928>

Ezzikouri, S., Tajudeen, R., Majidi, H., Redwane, S., Aqillouch, S., Abdulaziz, M., Aragaw, M., Papa Fallah, M., Sembuche, S., Batcho, S., Kabwe, P., Gonese, E., Laazaazia, O., Elmessaoudi-Idrissi, M., Meziane, N., Ainahi, A., Sarih, M., Ogwell Ouma, A. E., & Maaroufi, A. (2024). Seroepidemiological assessment of SARS-CoV-2 vaccine



ness and associated factors in the vaccinated community of the Casablanca-
tion, Morocco. *Scientific Reports*, 14(1), 7817. <https://doi.org/10.1038/s41598->

- Falahi, S., & Kenarkoochi, A. (2022). Host factors and vaccine efficacy: Implications for COVID-19 vaccines. *Journal of Medical Virology*, 94(4), 1330–1335. <https://doi.org/10.1002/jmv.27485>
- Gesmalah, M., & Hidajah, A. C. (2021). Epidemiological pattern of covid-19 infection from march to november 2020 in situbondo district, east java, Indonesia. *Kesmas*, 16(5), 23–28. <https://doi.org/10.21109/kesmas.v0i0.5049>
- Guglielmi, V., Colangeli, L., Scipione, V., Ballacci, S., Stefano, M. D., Hauser, L., Bisogno, M. C., D'Adamo, M., Medda, E., & Sbraccia, P. (2022). Inflammation, underweight, malignancy and a marked catabolic state as predictors for worse outcomes in COVID-19 patients with moderate-to-severe disease admitted to Internal Medicine Unit. *PLoS ONE*, 17(5), e0268432. <https://doi.org/10.1371/journal.pone.0268432>
- Güzel, E. Ç., Çelikkol, A., Erdal, B., & Sedef, N. (2021). Immunogenicity after CoronaVac vaccination. *Revista Da Associação Médica Brasileira*, 67(10), 1403–1408. <https://doi.org/10.1590/1806-9282.20210389>
- Heidary, M., Kaviar, V. H., Shirani, M., Ghanavati, R., Motahar, M., Sholeh, M., Ghahramanpour, H., & Khoshnood, S. (2022). A Comprehensive Review of the Protein Subunit Vaccines Against COVID-19. *Frontiers in Microbiology*, 13, 927306. <https://doi.org/10.3389/fmicb.2022.927306>
- Hsieh, M.-J., Tsai, P.-H., Chiang, P.-H., Kao, Z.-K., Zhuang, Z.-Q., Hsieh, A.-R., Ho, H.-L., Chion, S.-H., Liang, K.-H., & Chen, Y.-C. (2024). Genomic insights into mRNA vaccine efficacy: Linking genetic polymorphisms to waning immunity. *Vaccines & Immunotherapeutics*, 20(1), 2399382.



<https://doi.org/10.1080/21645515.2024.2399382>

Hsieh, S.-M., Liu, W.-D., Huang, Y.-S., Lin, Y.-J., Hsieh, E.-F., Lian, W.-C., Chen, C., Janssen, R., Shih, S.-R., Huang, C.-G., Tai, I.-C., & Chang, S.-C. (2021). Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC-COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study. *EClinicalMedicine*, 38, 100989. <https://doi.org/10.1016/j.eclinm.2021.100989>

Hua, Q., Zhang, H., Yao, P., Xu, N., Sun, Y., Lu, H., Xu, F., Liao, Y., Yang, J., Mao, H., Zhang, Y., Zhu, H., Hu, X., Lv, H., & Jiang, J. (2022). Immunogenicity and immune-persistence of the CoronaVac or Covilo inactivated COVID-19 Vaccine: A 6-month population-based cohort study. *Frontiers in Immunology*, 13, 939311. <https://doi.org/10.3389/fimmu.2022.939311>

Huang, C.-F., Jang, T.-Y., Wu, P.-H., Kuo, M.-C., Yeh, M.-L., Wang, C.-W., Liang, P.-C., Wei, Y.-J., Hsu, P.-Y., Huang, C.-I., Hsieh, M.-Y., Lin, Y.-H., Hsiao, H.-H., Hsu, C.-M., Huang, C.-T., Lee, C.-Y., Chen, Y.-H., Chen, T.-C., Lin, K.-D., ... Yu, M.-L. (2023). Impact of comorbidities on the serological response to COVID-19 vaccination in a Taiwanese cohort. *Virology Journal*, 20(1), 112. <https://doi.org/10.1186/s12985-023-02056-5>

Jiang, G., Zou, Y., Zhao, D., & Yu, J. (2024). Optimising vaccine immunogenicity in ageing populations: Key strategies. *The Lancet Infectious Diseases*, 0(0). [https://doi.org/10.1016/S1473-3099\(24\)00497-3](https://doi.org/10.1016/S1473-3099(24)00497-3)



Kesehatan Republik Indonesia. (2022). *Data Vaksin Nasional*. sin.kemkes.go.id/#/vaccines

- Khanna, K., Sharma, S., & Gupta, D. K. (2018). Hydrometrocolpos etiology and management: Past beckons the present. *Pediatric Surgery International*, 34(3), 249–261. <https://doi.org/10.1007/s00383-017-4218-9>
- Klein, S. L. (2012). Immune Cells Have Sex and So Should Journal Articles. *Endocrinology*, 153(6), 2544–2550. <https://doi.org/10.1210/en.2011-2120>
- Klein, S. L., & Flanagan, K. L. (2016). Sex differences in immune responses. *Nature Reviews. Immunology*, 16(10), 626–638. <https://doi.org/10.1038/nri.2016.90>
- Ko, Y. K., Murayama, H., Yamasaki, L., Kinoshita, R., Suzuki, M., & Nishiura, H. (2022). Age-Dependent Effects of COVID-19 Vaccine and of Healthcare Burden on COVID-19 Deaths, Tokyo, Japan. *Emerging Infectious Diseases*, 28(9), 1777. <https://doi.org/10.3201/eid2809.220377>
- Li, Z., Liu, X., Liu, M., Wu, Z., Liu, Y., Li, W., Liu, M., Wang, X., Gao, B., Luo, Y., Li, X., Tao, L., Wang, W., & Guo, X. (2021). The Effect of the COVID-19 Vaccine on Daily Cases and Deaths Based on Global Vaccine Data. *Vaccines*, 9(11). <https://doi.org/10.3390/vaccines9111328>
- Liana, P., Hafy, Z., Fertilita, S., Amalia, E., Larasati, V., & Umar, T. P. (2023). The polymorphisms of TNF- α related-gene and antibody production following third dose of COVID-19 vaccination: A pilot study. *Vacunas*, 24(4), 273–277. <https://doi.org/10.1016/j.vacun.2023.04.002>
- Lord, J. M. (2013). The effect of aging of the immune system on vaccination responses. *Human Vaccines & Immunotherapeutics*, 9(6), 1364. <https://doi.org/10.4161/hv.24696>
- Seco, J., López-Pérez, L.-R., González-Pérez, J.-M., Rosón, B., Otero-Barrós, rán-Parrondo, C., Nartallo-Penas, V., Mirás-Carballal, S., Rodríguez-Tenreiro,



- C., Rivero-Calle, I., Gómez-Carballa, A., Salas, A., & Martín-Torres, F. (2022). Effectiveness of COVID-19 vaccine booster in the general population and in subjects with comorbidities. A population-based study in Spain. *Environmental Research*, 215(Pt 2), 114252. <https://doi.org/10.1016/j.envres.2022.114252>
- Manomaipiboon, A., Phumisantiphong, U., Maneerit, J., Chalearmchai, Y., Jirawathin, W., Prajongsai, A., Phankavong, P., & Trakarnvanich, T. (2022). Immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 with 12-dose vials: An interim analysis. *Vaccine*, 40(4), 587–593. <https://doi.org/10.1016/j.vaccine.2021.12.023>
- Marra, A. R., Kobayashi, T., Suzuki, H., Alsuhaibani, M., Hasegawa, S., Tholany, J., Perencevich, E., Maezato, A. M., Ricardo, V. C. V., Salinas, J. L., Edmond, M. B., & Rizzo, L. V. (2022). The effectiveness of coronavirus disease 2019 (COVID-19) vaccine in the prevention of post-COVID-19 conditions: A systematic literature review and meta-analysis. *Antimicrobial Stewardship & Healthcare Epidemiology: ASHE*, 2(1), e192. <https://doi.org/10.1017/ash.2022.336>
- Masyeni, S., Johar, E., Budhitresna, A. A. G., Mahardika, N., Dewi, N. R. K., Widiana, I. G. R., Yudhaputri, F. A., & Myint, K. S. A. (2022). Immunogenicity and Reactogenicity of CoronaVac: A Cohort Study. *COVID*, 2(4), 485–491. <https://doi.org/10.3390/covid2040035>
- Moghadas, S. M., Vilches, T. N., Zhang, K., Wells, C. R., Shoukat, A., Singer, B. H., Meyers, L. A., Neuzil, K. M., Langley, J. M., Fitzpatrick, M. C., & Galvani, A. P. (2021). The impact of vaccination on COVID-19 outbreaks in the United States. In *medRxiv: The preprint server for health sciences*. <https://doi.org/10.1101/2020.11.27.20240051>
- , T. H., Moola, S., Tufanaru, C., Stern, C., McArthur, A., Stephenson, M., &



Aromataris, E. (2020). Methodological quality of case series studies: An introduction to the JBI critical appraisal tool. *JBIC Evidence Synthesis*, 18(10), 2127–2133. <https://doi.org/10.11124/JBISIR-D-19-00099>

Naruse, H., Ito, H., Izawa, H., Sarai, M., Ishii, J., Sakaguchi, E., Murakami, R., Ando, T., Fujigaki, H., & Saito, K. (2021). Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine in Patients with Cardiovascular Disease. *Journal of Clinical Medicine*, 10(23), Article 23. <https://doi.org/10.3390/jcm10235498>

Ng, H.-Y., Liao, Y., Zhang, R., Chan, K.-H., To, W.-P., Hui, C.-H., Seto, W.-K., Leung, W. K., Hung, I. F. N., Lam, T. T. Y., & Cheung, K.-S. (2024). The Predictive Value of Gut Microbiota Composition for Sustained Immunogenicity following Two Doses of CoronaVac. *International Journal of Molecular Sciences*, 25(5), 2583. <https://doi.org/10.3390/ijms25052583>

Nurdin, A., Movieta Nancy, Y., Maddeppungeng, M., Sekartini, R., Mulia Sari, R., Surachman, F., Fitry Yani, F., Raveinal, Anggrainy, F., Hafiz, A., Linosefa, Machmud, R., Awaliyah Deza, P., Rujiana, V., Bella Rahimi, M., Farhanah, N., Gundi Pramudo, S., Hapsari, R., Tri Anantyo, D., ... Soedjatmiko. (2024). Immunogenicity and safety of SARS-CoV-2 recombinant protein subunit vaccine (IndoVac) adjuvanted with alum and CpG 1018 in Indonesian adults: A phase 3, randomized, active-controlled, multicenter trial. *Vaccine*, 42(12), 3009–3017. <https://doi.org/10.1016/j.vaccine.2024.03.077>

O'Meara, T. R., Nanishi, E., McGrath, M. E., Barman, S., Dong, D., Dillen, C., Menon, M., Seo, H.-S., Dhe-Paganon, S., Ernst, R. K., Levy, O., Frieman, M. B., & Dowling, D. J. (2023).



SARS-CoV-2 mRNA vaccine immunogenicity and protection in mice with diet-besity and insulin resistance. *Journal of Allergy and Clinical Immunology*,

152(5), 1107-1120.e6. <https://doi.org/10.1016/j.jaci.2023.06.031>

Ou, X., Jiang, J., Lin, B., Liu, Q., Lin, W., Chen, G., & Wen, J. (2022). Antibody responses to COVID-19 vaccination in people with obesity: A systematic review and meta-analysis. *Influenza and Other Respiratory Viruses*, 17(1), e13078. <https://doi.org/10.1111/irv.13078>

Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville, J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., ... Moher, D. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. *BMJ*, 372, n71. <https://doi.org/10.1136/bmj.n71>

Peng, Y., Zhang, L., Mok, C. K. P., Ching, J. Y. L., Zhao, S., Wong, M. K. L., Zhu, J., Chen, C., Wang, S., Yan, S., Qin, B., Liu, Y., Zhang, X., Cheung, C. P., Cheong, P. K., Ip, K. L., Fung, A. C. H., Wong, K. K. Y., Hui, D. S. C., ... Tun, H. M. (2023). Baseline gut microbiota and metabolome predict durable immunogenicity to SARS-CoV-2 vaccines. *Signal Transduction and Targeted Therapy*, 8(1), 373. <https://doi.org/10.1038/s41392-023-01629-8>

Porntharukchareon, T., Chartisathian, W., Navinpipat, M., Samdaengpan, C., Cheirsilpa, K., Lueprasitsakul, A., Worawichawong, S., Muangsillapasart, V., Pumuthaivirat, P., Dechates, B., Sirisreetreerux, S., Siripongboonsitti, T., Rangrisaeneepitak, V., Jirawattanapalin, K., & Tawinprai, K. (2023). The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective



study. *Human Vaccines & Immunotherapeutics*, 19(2), 2251850. <https://doi.org/10.1080/21645515.2023.2251850>

- Rahman, M. M., Masum, M. H. U., Wajed, S., & Talukder, A. (2022). A comprehensive review on COVID-19 vaccines: Development, effectiveness, adverse effects, distribution and challenges. *Virusdisease*, 33(1), 1–22. <https://doi.org/10.1007/s13337-022-00755-1>
- Rao, B., Wang, L., Yang, M., Luo, H., Sun, J., Liu, S., Wang, H., Wang, X., Li, L., Yuan, C., Yu, Z., & Ren, Z. (2024). Safety and immunogenicity of CoronaVac in healthy adults: A prospective observational multicenter real-world study in Henan Province, China. *Virulence*, 15(1), 2310450. <https://doi.org/10.1080/21505594.2024.2310450>
- Ray, S., Narayanan, A., Vesterbacka, J., Blennow, O., Chen, P., Gao, Y., Gabarrini, G., Ljunggren, H.-G., Buggert, M., Manoharan, L., Chen, M. S., Aleman, S., Sönnernborg, A., & Nowak, P. (2023). Impact of the gut microbiome on immunological responses to COVID-19 vaccination in healthy controls and people living with HIV. *Npj Biofilms and Microbiomes*, 9(1), 1–12. <https://doi.org/10.1038/s41522-023-00461-w>
- Rifai, A., Wahono, C. S., Pratama, M. Z., Handono, K., Susianti, H., Iskandar, A., Diyah, N., Santoningsih, D., Samsu, N., & Gunawan, A. (2022). Association Between the Effectiveness and Immunogenicity of Inactivated SARS-CoV2 Vaccine (CoronaVac) with the Presence of Hypertension among Health Care Workers. *Clinical and Experimental Hypertension (New York, N.Y.: 1993)*, 44(3), 233–239. <https://doi.org/10.1080/10641963.2021.2022687>
- Rodríguez-Martínez, L. M., Chavelas-Reyes, J. L., Medina-Ramírez, C. F., Cabrera-Santos, F. J., Fernández-Santos, N. A., Aguilar-Durán, J. A., Pérez-Tapia, S. M., Rodríguez-González, I. G., & Rodríguez Pérez, M. A. (2024). Gender, Immunological Response, and COVID-19 Assessment of Vaccine Strategies in a Pandemic Region of Oaxaca, México. *Microbiology Research*, 15(2), Article 2. <https://doi.org/10.3390/microbiolres15020066>



Santi, T., Samakto, B. D., Kamarga, L., Hidayat, F. K., & Hidayat, F. (2021). Factors Associated with SARS-CoV-2 Antibody Titer After Sinovac Vaccination Among Health Care Workers. *Acta Med Indones*, 53(4).

Setiadi, W., Rozi, I. E., Safari, D., Daningrat, W. O. D., Johar, E., Yohan, B., Yudhaputri, F. A., Lestari, K. D., Oktavianthi, S., Myint, K. S. A., Malik, S. G., & Soebandrio, A. (2022). Prevalence and epidemiological characteristics of COVID-19 after one year of pandemic in Jakarta and neighbouring areas, Indonesia: A single center study. *PloS One*, 17(5), e0268241. <https://doi.org/10.1371/journal.pone.0268241>

Setiawaty, V., Kosasih, H., Mardian, Y., Ajis, E., Prasetyowati, E. B., & Karyana, M. (2020). The Identification of First COVID-19 Cluster in Indonesia. *The American Journal of Tropical Medicine and Hygiene*, 103(6), 2339–2342. <https://doi.org/10.4269/ajtmh.20-0554>

Smatti, M. K., Alkhatib, H. A., Al Thani, A. A., & Yassine, H. M. (2022). Will Host Genetics Affect the Response to SARS-CoV-2 Vaccines? Historical Precedents. *Frontiers in Medicine*, 9. <https://doi.org/10.3389/fmed.2022.802312>

Soegiarto, G., Wulandari, L., Purnomosari, D., Fahmita, K. D., Gautama, H. I., Hadmoko, S. T., Prasetyo, M. E., Mahdi, B. A., Arafah, N., Prasetyaningtyas, D., Negoro, P. P., Prakoeswa, C. R. S., Endaryanto, A., Suprabawati, D. G. A., Tinduh, D., Rachmad, E. B., Triyono, E. A., Wahyuhadi, J., Keswardiono, C. B., ... Oceandy, D. (2022). Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2. *Vaccine*, 40(30),

[s://doi.org/10.1016/j.vaccine.2022.05.059](https://doi.org/10.1016/j.vaccine.2022.05.059)

eri, S., Moradpour, F., Mohammadzede, P., Zareie, M., Mortazavi, S. M. M.,



- Manifar, S., Kohan, H. G., & Moradi, Y. (2023). The efficacy and effectiveness of COVID-19 vaccines around the world: A mini-review and meta-analysis. *Annals of Clinical Microbiology and Antimicrobials*, 22(1), 42. <https://doi.org/10.1186/s12941-023-00594-y>
- Trakarnvanich, T., Ngamvichchukorn, T., Phumisantiphong, U., Pholtawornkulchai, K., Phochanasomboon, K., & Manomaipiboon, A. (2022). Immune response after COVID-19 vaccination among patients with chronic kidney disease and kidney transplant. *Vaccine*, 40(45), 6499. <https://doi.org/10.1016/j.vaccine.2022.09.067>
- Tsang, T. K., Wang, C., Tsang, N. N. Y., Fang, V. J., Perera, R. A. P. M., Malik Peiris, J. S., Leung, G. M., Cowling, B. J., & Ip, D. K. M. (2023). Impact of host genetic polymorphisms on response to inactivated influenza vaccine in children. *Npj Vaccines*, 8(1), 1–5. <https://doi.org/10.1038/s41541-023-00621-1>
- Varghese, S. M., Mateethra, G. C., George, G., Chandran, V. S., John, G. M., Varghese, L. T., Mammen, N. K., & Vinayak, V. (2022). A study on seroconversion following first & second doses of ChAdOx1 nCoV-19 vaccine in Central Kerala. *Indian Journal of Medical Research, Publish Ahead of Print*. https://doi.org/10.4103/ijmr.ijmr_1917_21
- Vasilev, G., Kabakchieva, P., Miteva, D., Batselova, H., & Velikova, T. (2022). Effectiveness and safety of COVID-19 vaccines in patients with diabetes as a factor for vaccine hesitancy. *World Journal of Diabetes*, 13(9), 738. <https://doi.org/10.4239/wjd.v13.i9.738>
- Watson, O. J., Barnsley, G., Toor, J., Hogan, A. B., Winskill, P., & Ghani, A. C. (2022). Global impact of the first year of COVID-19 vaccination: A mathematical modelling study. *The Infectious Diseases*, 22(9), 1293–1302. <https://doi.org/10.1016/S1473-0320-6>



World Health Organization. (2023). *COVID-19 Weekly Epidemiological Update*.

Wu, N., Joyal-Desmarais, K., Ribeiro, P. A. B., Vieira, A. M., Stojanovic, J., Sanuade, C., Yip, D., & Bacon, S. L. (2023). Long-term effectiveness of COVID-19 vaccines against infections, hospitalisations, and mortality in adults: Findings from a rapid living systematic evidence synthesis and meta-analysis up to December, 2022. *The Lancet Respiratory Medicine*, 11(5), 439–452. [https://doi.org/10.1016/S2213-2600\(23\)00015-2](https://doi.org/10.1016/S2213-2600(23)00015-2)

Yalçın, T. Y., Topçu, D. İ., Doğan, Ö., Aydın, S., Sarı, N., Erol, Ç., Kuloğlu, Z. E., Azap, Ö. K., Can, F., & Arslan, H. (2022). Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study. *Journal of Medical Virology*, 94(1), 279–286. <https://doi.org/10.1002/jmv.27316>

Yang, M.-C., Wang, C.-C., Tang, W.-C., Chen, K.-M., Chen, C.-Y., Lin, H.-H., Hsieh, Y.-C., Wang, N.-H., Kuo, Y.-C., Chu, P.-T., Tung, H.-Y., Wu, Y.-C., Sun, J.-L., Liu, S.-Y., Li, W.-F., Lee, W.-H., Lai, J.-S., Chang, M., & Lai, M.-T. (2023). Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies. *PloS One*, 18(3), e0283473. <https://doi.org/10.1371/journal.pone.0283473>

Zhang, L.-N., Tan, J.-T., Ng, H.-Y., Liao, Y.-S., Zhang, R.-Q., Chan, K.-H., Hung, I. F.-N., Lam, T. T.-Y., & Cheung, K.-S. (2024). Association between Gut Microbiota Composition and Long-Term Vaccine Immunogenicity following Three Doses of CoronaVac. *Vaccines*, 12(4), Article 4. <https://doi.org/10.3390/vaccines12040365>

